摘要
目的 :探讨多药耐药蛋白和bcl 2蛋白表达与初治急性白血病 (AL)患者化疗效果的关系。方法 :用流式细胞仪检测 2 9例初诊未治AL患者多药耐药蛋白和bcl 2蛋白表达。结果 :初治AL患者多药耐药蛋白和bcl 2蛋白表达率分别为 37.9%和 83% ;bcl 2蛋白阳性与阴性患者的首次完全缓解 (CR)情况经统计学分析显示差异无显著性 (P >0 .0 5 ) ;而多药耐药蛋白阳性与阴性患者的首次完全缓解 (CR)情况经统计学分析显示有显著性差异 (P <0 .0 5 ) ;多药耐药蛋白和bcl 2蛋白两者之间无相关性。结论 :多药耐药蛋白可作为预测初治AL患者化疗效果的敏感性指标。
Objective: To Evaluate the relationship between the expression of multidrug resistance protein or bcl-2 protein and prognosis in newly diagnosed AL patients. Methods: Immunochemistry and FCM methods were used to examine the expression of multidrug resistance protein and bcl-2 protein in 29 newly diagnosed acute leukemia (AL) patients. Results: The positive rate of multidrug resistance protein and bcl-2 protein expression in newly diagnosed AL was 37.9% and 83% respectively. The difference of the first complete remission rate in bcl-2 negative and in bcl-2 positive patients was not significant (P>0.05),but the difference of the first complete remission rate in multidrug resistance protein negative and in multidrug resistance protein positive patients was significant (P<0.05).There was no relationship between bcl-2 and multidrug resistance protein. Conclusion: Multidrug resistance protein is a good indicator to forecast prognosis in newly diagnosis leukemia patients.
出处
《军医进修学院学报》
CAS
2004年第1期42-43,共2页
Academic Journal of Pla Postgraduate Medical School
基金
军队"九五"攻关课题基金资助 ( 96Z0 2 3 )
